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Available online xxxxAlzheimer's disease (AD) is a progressive neurodegenerative disease affecting millions of patients worldwide.
Previous studies have demonstrated alterations in the lipid composition of lipid extracts from plasma and
brain samples of AD patients. However, there is no consensus regarding the qualitative and quantitative changes
of lipids in brains fromAD patients. In addition, the recent developments in imagingmass spectrometrymethods
are leading to a new stage in the in situ analysis of lipid species in brain tissue slices fromhuman postmortem sam-
ples. The present study uses thematrix-assisted laser desorption/ionization imagingmass spectrometry (MALDI-
IMS), permitting the direct anatomical analysis of lipids in postmortem brain sections fromAD patients, which are
compared with the intensity of the lipid signal in samples frommatched subjects with no neurological diseases.
The frontal cortex samples from AD patients were classiﬁed in three groups based on Braak's histochemical
criteria, ranging fromnon-cognitively impaired patients to those severely affected. Themain results indicate a de-
pletion of different sulfatide lipid species from the earliest stages of the disease in both white and gray matter
areas of the frontal cortex. Therefore, the decrease in sulfatides in cortical areas could be considered as a marker
of the disease, but may also indicate neurochemicalmodiﬁcations related to the pathogenesis of the disease. This
article is part of a Special Issue entitled: Membrane Lipid Therapy: Drugs Targeting Biomembranes edited by
Pablo Escríba-Ruíz.
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Human1. Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease
affecting millions of patients worldwide. It is clinically characterized by
progressive cognitive impairment, and neuropathologically, by the ap-
pearance of extracellular neuritic plaques and intraneuronal neuroﬁ-
brillary tangles (NFT), together with a loss of synapses and neurons
and the accumulation of lipid granules [1–3]. The neuritic plaques are
largely composed of a dense amyloid core of β-amyloid (Aβ) peptide,
which is generated by the amyloid precursor protein (APP) via therption/ionization imaging mass
, neuroﬁbrillary tangles; Aβ, β-
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(2017), http://dx.doi.org/10.1sequential cleavage of APP by the β-secretase (β-site APP cleavage en-
zyme 1; BACE1) [4,5]. The NFT consist of a hyperphosphorylated form
of the tau protein [6]. Moreover, the NFT are used as postmortem diag-
nostic criteria and also for the classiﬁcation of AD patients in Braak's
stages I to VI based on the severity of the disease [7].
Furthermore, there is now evidence that lipid molecules have a rel-
evant role both in cell membrane composition and neurotransmitter
signaling in different neurodegenerative diseases, such as AD [8]. Lipid
molecules could also be involved in amyloidogenesis by the regulation
of APP, BACE1 and the component of γ-secretase complex, since all of
them are components of lipidic bilayers [9]. The composition and orga-
nization of lipids in the cell membranes determine the trafﬁcking prop-
erties of proteins and metabolites with important consequences in cell
signaling and physiology [10].
On the other hand, tau is a cytoplasmic protein that stabilizesmicro-
tubules that can bemodulated by lipidmolecules in different ways [11–
14]. Some neurodegenerative diseases such as Niemann-Pick type C is
characterized by the accumulation of cholesterol and glycolipids in lyso-
somes, together with the presence of NFT tangles, suggesting that lipid
deregulation is involved in tau pathologies [15].
The lipid composition has also been analyzed in tissue homogenates
(lipid fraction) from brain samples of AD patients. Total phospholipidectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Table 1
Values are means ± SEM.
Samples n Age (years) Postmortem (hours)
Total ♂ ♀
Control 5 5 0 60.8 ± 4.7 6.15 ± 2.19
AD
I–II 5 3 2 66.4 ± 3.4 6.10 ± 1.3
III–IV 5 4 1 75.8 ± 4.3 9.10 ± 2.0
V–VI 5 2 3 74.6 ± 2.0 5.45 ± 1.0
2 E. Gónzalez de San Román et al. / Biochimica et Biophysica Acta xxx (2017) xxx–xxxand sulfatide (ST) composition were found to be decreased in AD pa-
tients as compared to control subjects [16–19], in contrast to the in-
crease in ceramide (Cer) and cholesterol content [18,20]. Cer levels in
the cerebrospinal ﬂuid (CSF)were also found to be increased in patients
with AD [21], as was the level and activity of acid ceramidase in the
fronto-temporal gray matter [22]. However, more recent studies de-
scribed a decrease in ceramide synthase 2 activity, necessary for myelin
biosynthesis, which precedes tau pathology [23]. Other changes have
also been reported in the phospholipid composition of the brain, in
CSF and also in plasma during different stages of AD [24–27]. A recent
study analyzing more than 500 plasma samples from AD patients, re-
ported eight phosphatidylcholine lipid species (PC) as possible bio-
markers for AD and which predicted phenoconversion to eitherFig. 1. Average spectra comparison between controls and AD patients. Mass spectrawere obtain
matter from the frontal cortex of the tissue slices. The spectra parameterswereobtained using 2
15–20 μJ and usingMBTmatrix. Detection was performed in negative ionmode. The “y” axis re
maximal peak is the most intense peak of the spectrum, in this case 885.5494 PI (20:4/18:0) w
Please cite this article as: E. Gónzalez de San Román, et al., Imagingmass s
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1amnestic mild cognitive impairment (MCI) or to Alzheimer's disease
within a 2 to 3 year timeframe, with over 90% accuracy [28].
In this context, the development of mass spectrometry during the
last decade has provided us with a very useful tool not only for
lipidomics, but also for the imaging of lipid species directly in situwith
unprecedented anatomical localization, enabling the simultaneous
analysis of numerous phospholipid classes using a single slice of tissue.
The great potential of the new technique of matrix-assisted laser de-
sorption/ionization imaging mass spectrometry (MALDI-IMS) in ana-
tomical analysis has accelerated its development and applications
[29–32], providing information about lipid mapping in different tissues
[33]. Nevertheless, there are very few studies applying IMS to human
postmortem brain tissue samples [34–36].
There is extensive knowledge of the biochemistry of AD, but the bio-
chemical mechanisms underlying the pathogenesis of the disease still
remain unknown, and the approved therapeutic approaches are not ef-
fective. The aim of the present study was to ﬁnd possible lipid regula-
tions during the progression of AD in cortical areas that are affected by
tau and amyloid histopathological markers by clearly discriminating
the cortical layers from the adjacent white matter. Using MALDI-IMS
we analyzed the anatomical distribution of lipids in postmortem
human brain samples of frontal cortex (Brodmann area 8) from AD pa-
tients classiﬁed in three different groups (I–II, III–IV and V–VI) based on
disease severity according to I–VI Braak's stages.ed from the average spectra recorded directly from the tissue slice, selecting only the gray
micro scans/stepwith 10 laser shots and a raster step size of 150 μmwith the laser power at
presents the intensity of themeasuredMS signal as a percentage of the maximal peak. The
hich is set at 100%.
pectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Table 2
Percentage of the relative intensity of representative lipids in gray matter of postmortem human frontal cortex of controls and AD patients in negative ion detection mode. The maximal
peak is the most intense peak of the spectrum, in this case 885.5494 PI (20:4/18:0) which is set at 100%.
Assignment Cal m/z Exp m/z % intensity
Control AD I–II AD III–IV AD V–VI
CPE (38:1) 715.5760 715.5735 23.5 ± 6.3 37.4 ± 6.4 35.5 ± 10.3 29.5 ± 1.5
SM (d37:1) 743.6073 743.6052 12.9 ± 2.0 13.7 ± 2.9 9.6 ± 2.5 10.6 ± 0.5
PS (18:0/18:1) 788.5442 788.5429 1.8 ± 0.9 0.5 ± 1.5 2.0 ± 1.1 1.7 ± 0.9
PE (18:0/22:6) 790.5381 790.5373 4.3 ± 1.4 3.8 ± 1.3 3.5 ± 0.7 3.9 ± 0.7
ST (d18:1/18:0) 806.5451 806.5443 1.7 ± 0.2 0.5 ± 0.2a 0.5 ± 0.1b 0.8 ± 0.1
PS (40:6) 834.5291 834.5282 13.6 ± 3.2 12.3 ± 2.6 13.9 ± 4.1 10.2 ± 1.2
PI (16:0/20:4) 857.5186 857.5174 9.3 ± 0.8 10.7 ± 1.0 10.5 ± 1.0 10.1 ± 0.7
ST (d18:1/h22:0) 878.6033 878.6078 6.7 ± 1.5 2.8 ± 0.8 2.6 ± 0.3b 2.8 ± 0.7c
PI (18:1/20:4) 883.5337 883.5320 8.5 ± 1.3 8.8 ± 1.8 7.6 ± 1.3 7.1 ± 1.1
ST (d18:1/24:1) 888.6240 888.6215 37.6 ± 4.7 18.6 ± 6.6a 16.0 ± 2.3b 24.0 ± 2.8
ST (d18:1/24:0) 890.6395 890.6348 8.1 ± 1.5 2.9 ± 0.9a 3.8 ± 0.2b 7.3 ± 0.9
ST (d18:1/h23:0) or ST (d18:0/h24:0) 892.6189 892.6352 16.5 ± 3.9 5.0 ± 1.5a 6.4 ± 0.2 8.1 ± 1.0
CPI (40:2) + MBT 896.5779 896.5738 3.5 ± 0.9 20.5 ± 5.8a 11.3 ± 2.8 9.7 ± 1.3
ST (d18:1/25:1) or (d18:2/25:0) 902.6396 902.6380 13.7 ± 2.0 5.3 ± 2.2 5.0 ± 0.6b 8.3 ± 0.6
ST (d18:1/h24:1) 904.6188 904.6150 38.2 ± 7.5 16.2 ± 4.4 15.5 ± 1.3b 17.2 ± 0.8
ST (d18:1/h24:0) 906.6345 906.6295 43.6 ± 10.3 11.6 ± 3.7a 15.2 ± 0.5 18.4 ± 1.9
PI(18:0/22:6) 909.5488 909.5472 5.8 ± 0.8 5.1 ± 0.5 5.7 ± 0.8 5.8 ± 0.2
ST (d18:1/h25:1) or (d18:2/h25:0) 918.6346 918.6308 10.9 ± 2.1 3.8 ± 1.1a 3.6 ± 0.4b 5.0 ± 0.5
ST (d18:1/h25:0) 920.6502 920.6464 7.7 ± 2.2 4.9 ± 1.6 3.6 ± 1.2 5.0 ± 0.5
ST (d18:1/h26:1) 932.6502 932.6471 11.8 ± 2.7 4.7 ± 1.3 3.2 ± 0.7b 6.1 ± 0.6
Data aremean±SEM. The p valueswere calculated by the Kruskal-Wallis non-parametric test followed byDunn's test. Control (n=5), AD I–II (n=5), AD III-IV (n=5), ADV–VI (n=5).
Cal: calculated, Exp: experimental. The notation (hX:Y) denotes hydroxylated sulfatide species.
a AD I–II vs control.
b AD III–IV vs control.
c AD V–VI vs control.
Fig. 2. Comparison of average mass spectra from controls (n= 5) and AD patients, obtained from the average spectra recorded directly from the tissue slice, selecting only white matter.
The spectra parameters were 2 micro scans/step with 10 laser shots and a raster step size of 150 μmwith the laser power at 15–20 μJ and using MBT matrix. Detection is performed in
negative ion mode. The “y” axis represents the intensity of the measured MS signal as percentage of the maximal peak. The maximal peak is the most intense peak in this case
888.6254 ST (18:0/20:4) of the spectrum, which is set at 100%.
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Table 3
Percentage of the relative intensity of representative lipids in white matter of postmortem human frontal cortex of controls and AD patients in negative ion detection mode. The maximal
peak is the most intense peak of the spectrum, in this case 888.6240 ST (d18:1/24:1) which is set at 100%.
Assignment Cal m/z Exp m/z % intensity
Control AD I–II AD III–IV AD V–VI
CPE (38:1) 715.5760 715.5735 3.3 ± 0.8 7.0 ± 0.8 8.1 ± 0.6b 6.9 ± 1.6
PS (18:0/18:1) 788.5442 788.5428 6.1 ± 2.1 9.2 ± 3.1 9.2 ± 3.7 1.7 ± 0.2
SM (d41:2) 797.6542 797.6533 3.9 ± 0.9 6.8 ± 1.3 5.2 ± 1.3 6.1 ± 0.6
ST (18:0) 806.5451 806.5443 3.7 ± 0.8 3.1 ± 0.5 2.3 ± 0.2 2.1 ± 0.2
PI (34:1) 835.5342 835.5318 2.9 ± 0.5 3.8 ± 1.4 3.9 ± 1.2 2.6 ± 0.3
PI (16:0/20:4) 857.5186 857.5165 0.7 ± 0.2 1.8 ± 1.1 0.5 ± 0.2 0.5 ± 0.3
ST (22:0) 862.6077 862.6072 2.3 ± 0.3 1.2 ± 0.5 1.2 ± 0.5 1.6 ± 0.2
ST (d18:1/h22:0) 878.6033 878.6078 6.8 ± 0.8 5.4 ± 1.3 4.3 ± 1.2 3.2 ± 0.7
PI (18:0/20:4) 885.5494 885.5473 12.1 ± 1.1 9.8 ± 1.5 10.1 ± 1.1 9.2 ± 1.6
ST (24:0) 890.6395 890.6348 29.9 ± 4.1 22.3 ± 2.1 24.0 ± 0.8 19.9 ± 2.3
ST (d18:1/23:0) or ST (d18:0/24:0) 892.6189 892.6169 15.5 ± 2.0 9.3 ± 2.1 11.5 ± 2.8 8.0 ± 2.6
CPI (40:2) + MBT 896.5779 896.5779 0.2 ± 0.1 6.7 ± 2.4a 4.3 ± 1.6 1.8 ± 0.6
ST (d18:1/25:1) or (d18:2/25:0) 902.6396 902.6380 32.1 ± 3.0 21.3 ± 1.5a 26.1 ± 0.6 23.2 ± 0.3
ST (d18:1/h24:1) 904.6189 904.6150 49.7 ± 5.7 35.9 ± 2.2 33.7 ± 5.7 30.8 ± 3.2c
ST (d18:1/h24:0) 906.6345 906.6316 37.4 ± 5.0 22.8 ± 2.2 28.5 ± 4.5 20.0 ± 3.9
ST (d18:1/h25:1) or (d18:2/h25:0) 918.6346 918.6308 12.3 ± 2.0 7.2 ± 0.7 7.5 ± 0.9 6.1 ± 0.9c
ST (d18:1/h25:0) 920.6502 920.6455 7.4 ± 1.2 4.0 ± 0.2 6.1 ± 0.5 3.7 ± 0.9c
ST (d18:1/h26:1) 932.6502 932.6471 10.3 ± 0.8 5.3 ± 0.5a 7.8 ± 0.4 6.7 ± 1.4
Data aremean±SEM. The p valueswere calculated by the Kruskal-Wallis non-parametric test followed byDunn's test. Control (n=5), AD I–II (n=5), AD III-IV (n=5), ADV–VI (n=5).
Cal: calculated, Exp: experimental. The notation (hX:Y) denotes hydroxylated sulfatide species.
a AD I–II vs control.
b AD III–IV vs control.
c AD V–VI vs control.
4 E. Gónzalez de San Román et al. / Biochimica et Biophysica Acta xxx (2017) xxx–xxx2. Materials and methods
2.1. Brain sectioning
The humanbrain sampleswere supplied by the Institute of Neuropa-
thology (University Hospital Bellvitge, Barcelona). Human brains were
obtained at autopsy after prior informed consent and with the institu-
tional approval of the ethics committees of the University of the BasqueFig. 3. Representative images of thionine stained brain sections of control (A), AD I–II (B), AD
measurement in gray matter and the red oval areas are the ROI in white matter. Bar: 1 cm.
Please cite this article as: E. Gónzalez de San Román, et al., Imagingmass s
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1Country (UPV/EHU), following the Code of Ethics of the World Medical
Association (Declaration of Helsinki), and ensuring the privacy rights of
the human subjects. The control samples were obtained from 5 males
who had shown no evidence of neurological or metabolic disease. The
neuropathological study disclosed no abnormalities in the brain. The
AD sampleswere obtained from15males and femaleswith AD at differ-
ent Braak's stages. The intervals between death and autopsy were from
2.5 to 19 h (Table 1). Following autopsy, the brain samples wereIII–IV (C), AD V–VI (D). The black oval areas are the regions of interest (ROI) selected for
pectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Fig. 4. The image shows the distribution of representative lipid species that were found
modiﬁed when controls were compared with AD patients at different stages of the
disease. The color-coded images show areas of gray and white matter in the frontal
cortex of human brain tissue. The spectra were recorded with 150 μm spacing. Ten shots
were accumulated at each point with the spectrometer working in negative ion mode.
Laser power was set at 15–20 μJ. Bar : 3 mm.
Fig. 5. Average mass spectra in positive ion mode from control subjects and AD patients
selecting only gray matter. The spectra parameters were 2 micro scans/step with 10
laser shots and a raster step size of 150 μm with the laser power at 15–20 μJ and using
MBT matrix. The “y” axis represents the intensity of the measured MS signal as
percentage of the maximal peak. The maximal peak is the most intense peak of the
spectrum, in this case 798.60 PC (34:1) + K+, which is set at 100%.
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and 20 μm thick slices were obtained in a cryostat (Microm HM550,
Walldorf, Germany). Two consecutive sections were mounted on slides
and kept at−25 °C until they were treated with the chemical matrix
and introduced into a MALDI metal holder (LTQ orbitrap XL).
2.2. Thionine staining
Thionine staining was performed in consecutive sections to those
used inMALDI-IMS experiments to facilitate the identiﬁcation of neuro-
anatomical structures. Tissue slicesmounted onto gelatine-coated slides
were hydrated after thawing. Hydration was performed by incubating
tissue slices for 5 min in ethanol concentrations in a descending order
(100%, 96%, 70% and 50%). Then, sections were submerged in thionine
solution for 5 min. Finally, the sections were washed in deionized
water and introduced in an ethanol ascendant order solution (50%,
70%, 96% and 100%) to dehydrate the tissue. The thionine stained images
allowed us to delineate the area for MALDI scanning, including the six
layers of the cortex and the adjacent white matter.
2.3. Sample preparation
The original lipid composition and anatomical characteristics of the
tissue must be preserved throughout the sample-preparation process
[37]. The frontal cortex brain samples were sectioned and stored until
the moment of use, as described above.ectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Table 4
Percentage of the relative intensity of representative lipids in graymatter of postmortemhuman frontal cortex of controls andADpatients in positive ion detectionmode. Themaximal peak
is the most intense peak of the spectrum, in this case 798.60 PC (34:1) + K+, which is set at 100%.
Assignment Cal m/z Exp m/z % intensity
Control AD I–II AD III–IV AD V–VI
PA (34:1) + Na+ 697.4779 697.4785 12.9 ± 3.4 12.6 ± 3.8 10.7 ± 2.1 10.5 ± 2.1
GlcCer (d32:1) + K+ 710.4968 710.4912 20.0 ± 1.7 15.2 ± 3.2 14.9 ± 3.1 15.5 ± 0.7
PA (34:1) + K+ 713.4518 713.4525 29.1 ± 1.8 20.4 ± 3.6 21.7 ± 4.0 24.3 ± 2.3
PA (36:2) + Na+ 723.4935 723.4941 26.4 ± 4.9 23.8 ± 5.7 25.6 ± 3.5 22.3 ± 2.6
SM (d18:1/18:0) 731.6067 731.6083 2.7 ± 1.3 7.1 ± 0.9 7.6 ± 2.0 4.5 ± 0.6
PC (32:0) 734.5654 734.5688 18.1 ± 2.4 22.0 ± 1.6 22.7 ± 6.0 16.5 ± 3.4
PA (36:2) + K+ 739.4680 739.4685 50.9 ± 1.3 33.4 ± 3.6a 38.5 ± 4.0 40.9 ± 1.6
PA (38:2) + Na+ 751.5258 751.5248 4.3 ± 1.2 2.8 ± 0.5 2.9 ± 0.3 2.8 ± 0.5
SM (d18:1/18:0) + Na+ 753.5886 753.5896 20.8 ± 3.7 23.8 ± 4.9 24.2 ± 2.9 16.6 ± 2.0
PC (32:0) + Na+ 756.5519 756.5534 27.4 ± 5.1 31.7 ± 5.3 27.2 ± 5.1 28.8 ± 4.6
PC (34:2) 758.5654 758.5690 2.9 ± 0.5 3.0 ± 0.5 2.9 ± 0.4 2.3 ± 0.3
PC (34:1) 760.5856 760.5858 36.9 ± 5.7 46.3 ± 7.6 48.9 ± 10.8 38.1 ± 6.3
PA (38:2) + K+ 767.4988 767.5006 8.3 ± 0.5 2.2 ± 0.3a 5.7 ± 0.4 6.1 ± 0.5
SM (d18:1/18:0) 769.5626 769.5641 15.3 ± 1.8 14.5 ± 1.4 16.4 ± 1.4 11.4 ± 1.3
PC (32:0) + K+ 772.5259 772.5261 49.0 ± 4.3 54.6 ± 7.4 51.2 ± 5.1 53.3 ± 6.2
PC (34:2) + Na+ 780.5519 780.5533 2.8 ± 0.3 4.3 ± 0.5 3.5 ± 0.9 3.7 ± 0.9
PC (34:1) + Na+ 782.5675 782.5680 62.0 ± 10.3 67.9 ± 4.3 73.0 ± 6.3 75.8 ± 6.8
PC (36:3) 784.5856 784.5748 6.6 ± 0.9 8.8 ± 1.0 9.5 ± 1.3 7.1 ± 1.1
PC (36:1) 788.6164 788.6171 5.6 ± 1.1 6.8 ± 1.3 6.6 ± 2.1 5.3 ± 1.1
PC (34:2) + K+ 796.5259 796.5261 5.2 ± 0.9 6.0 ± 0.2 5.7 ± 0.8 5.5 ± 0.5
SM (d18:1/20:0) 797.5939 797.5943 12.4 ± 1.2 11.8 ± 1.7 11.8 ± 0.6 10.3 ± 1.2
PC (36:1) + Na+ 810.5988 810.5993 15.3 ± 1.8 14.5 ± 1.4 16.4 ± 1.4 11.4 ± 1.3
PC (34:6) + K+ 820.5259 820.5271 7.1 ± 1.9 6.9 ± 0.7 7.4 ± 1.0 5.7 ± 0.3
PC (36:1) + K+ 826.5728 826.5733 18.3 ± 0.7 16.8 ± 0.8 1 8.1 ± 1.0 15.6 ± 1.0
PC (38:4) + K+ 848.5572 848.5572 6.1 ± 1.6 6.1 ± 0.7 5.9 ± 0.8 4.2 ± 0.2
Data aremean±SEM. The p valueswere calculated by theKruskal-Wallis non-parametric test followed byDunn's test. Control (n=5), AD I–II (n=5), AD III–IV (n=5), ADV–VI (n=5).
Cal: calculated, Exp: experimental.
a AD I–II vs control.
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tion prior to analysis, using a glass sublimator (ACE glass 8023). Subli-
mation was performed using 300 mg of 2-mercaptobenzothiazole
(MBT), which has previously been reported as being an optimal chem-
ical matrix for phospholipid detection [38]. We controlled the deposi-
tion time and temperature (30 min, 140 °C) and the thickness of the
matrix layer, which optimized the signal/noise (s/n) ratio of the mass
spectra, and avoided lipid migration due to the absence of organic sol-
vents during the sublimation procedure. Finally, a recrystallization of
the samplewas performed using a normal glass Petri plate (100mmdi-
ameter × 15 mm depth), and 1 ml of methanol (99%) was added to a
piece of paper previously placed in the bottom of the Petri plate in
order to create a vapor atmosphere using a hot plate (1 min, 40 °C).
This step allowed us to achieve higher intensities in the detection of
the peaks in the mass spectra [39].2.4. MALDI imaging mass spectrometry
A MALDI LTQ-XL-Orbitrap (Thermo Fisher Scientiﬁc, Bremen, Ger-
many) equipped with a nitrogen laser (λ = 337 nm, rep. rate =
60Hz, spot size=80×120 μm)was used formass analysis. ImageQuest
1.0.1 software (Thermo Fisher Scientiﬁc, San Jose, CA, USA)was used for
MALDI-IMS data acquisition. The images were acquired in positive ion
mode in m/z range 500–1000 and in negative mode in m/z range 400–
1100 (depending on their charge) with 10 laser shots per point at
laserﬂuence of 15 μJ. However, from all the lipid species detectedwithin
those ranges, only the relative intensities of the most representative
lipid species, or those showing signiﬁcant modulations in patients are
showed. The target plate stepping distance was set to 150 μm for both
the x- and y-axes by the MSI image acquisition software. The mass res-
olution was 100,000 (full width at half maximum as deﬁned at m/z
400). As there may be potential displacement of the masses on the tis-
sue due to surface irregularities and other factors, it is necessary to nor-
malize them using the total ion current (TIC) [40].Please cite this article as: E. Gónzalez de San Román, et al., Imagingmass s
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.12.5. Image and spectra analysis of MALDI-IMS
The MALDI images were generated using ImageQuest software
(Thermo Scientiﬁc, San Jose, CA). The software provided a m/z
range that is plotted for signal intensity for each pixel (mass spec-
trum) across a given area (tissue section). The spectra normalization
was performed by TIC with MSIreader software [41]. The mean in-
tensity of two regions of interest (ROI) in white and grey matter re-
spectively was calculated using OriginPro 8 software of the ﬁve
samples in each group. The most intense peak was considered to be
100% and the rest of the peaks were normalized to the most abun-
dant species to compare the four groups. Differences between groups
of patients were analyzed by using the Kruskal-Wallis non-paramet-
ric test followed by Dunn's post-hoc test with GraphPad Prism (San
Diego, CA, USA) software. The results were considered signiﬁcant
when p ≤ 0.05 [42].2.6. Peak Assignment
The analysis of the lipid composition of tissue samples from
postmortem human brain used in the present study is complex. A
large number of different possible lipid species were detected and
some of them share similar masses and had not been detected
and/or assigned to a speciﬁc lipid molecule in previous studies.
Nevertheless, the assignment of lipid species was facilitated by
the use of databases such as Lipid MAPS (http://www.lipidmaps.
org/), Madison Metabolomics (http://mmcd.nmrfam.wisc.edu)
and previous reports [43–51]. For the assignment, 5 ppm mass ac-
curacy was selected as the tolerance window. The glycerolipid spe-
cies numbers (x:y) denote the total length and the number of
double bonds of the acyl chains, while the sphingolipid and
sulfatide species numbers correspond to the length and number
of double bonds of the acyl chain added to those of the attached
sphing-4-enine (d18:1) or sphinganine (d18:0) base.pectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Fig. 6. Average mass spectra in positive ionization detection mode corresponding to the
control group and the three groups of AD patients that were obtained selecting only
white matter. The spectra parameters were 2 micro scans/step with 10 laser shots and a
raster step size of 150 μm with the laser power at 15-20 μJ and using MBT matrix. The
“y” axis represents the intensity of the measured MS signal as percentage of the
maximal peak. The maximal peak is the most intense peak of the spectrum in this case
798.60 PC (34:1) + K+, which is set at 100%.
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TheMALDI-IMS technique represents a useful approach to direct an-
atomical localization of lipids in tissue sections. In the present study this
technique is applied to postmortem human brain sections of controls
and AD patients in positive and negative ion detection mode to obtain
anatomical images, which indicate the intensity of the signal for differ-
ent lipid species. The results were obtained from serial sections of
human brain samples of the frontal cortex area (Brodmann area 8).
We compared the data obtained from control subjects with those of
AD patients classiﬁed in three groups according to different Braak's
stages. Themean data for each group of patients was obtained, showing
the intensity of each lipid species in both white and gray matter sepa-
rately by using a speciﬁc image software, as described in the methods
section, thereby clearly differentiating the lipid composition of white
and gray matter. The detection of different lipid molecules, calculations
and statistical analysis were carried out for the molecular ions in nega-
tive and positivemode. The analyseswere carried out by normalizing by
TIC using theMSIreader software, and setting the peak with the highest
intensity at 100%, the rest of the peaks were normalized to the most
abundant species indicating a percentage of relative intensity. In the
case of negative ion mode in gray matter the maximal peak was the
phosphatidylinositol (PI) (20:4/18:0), and in white matter it was ST
(24:1). In contrast, in positive ion detection mode, the maximal peak
was PC (34:1) + K+ for both gray and white matter.Please cite this article as: E. Gónzalez de San Román, et al., Imagingmass sp
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1Firstly, MALDI-IMS analysis in negative ion detection mode demon-
strated that ST content was reduced bymore than 50% in graymatter of
frontal cortex from the earliest clinically identiﬁable stage of AD, the
group AD I–II (Fig. 1, Table 2).
In contrast, in white matter, there was a decrease in all ST species
from the earliest stages, which did not become statistically signiﬁcant
until the advanced stages of the disease, and then only for some speciﬁc
ST species (Fig. 2, Table 3).
Furthermore, we have observed an increase in ceramide-1-
phosphoinositol (CPI) (40:2) in the earliest stages of the disease in
both gray (Control 3.5 ± 0.9% vs AD I–II 20.5 ± 5.8%, p b 0.05) and
white matter (Control 0.2 ± 0.1% vs AD I–II 6.7 ± 2.4%, p b 0.05). How-
ever, in the most advanced stages of AD, CPI (40:2) decreased to inten-
sities comparable with those of control subjects. In addition, another
ceramide, ceramide-1-phosphoethanolamine (CPE) (38:1) was in-
creased only in white matter from the earliest stages and reached a
statistically signiﬁcant increase during moderate stages of AD (Control
3.3 ± 0.8% vs AD III–IV 8.1 ± 0.6%, p b 0.05). The thionine stained sec-
tions from control subjects and AD patients showed the different struc-
tures in the tissue sections and differentiated the areas of white and
gray matter selected for the IMS analysis (Fig. 3).
IMSmethod allowed us to obtain the anatomical distribution pattern
of lipids in color coded images, and showed the intensity of the lipids
that were modiﬁed in the cortical samples from AD patients (Figs. 4
and 7). The images showed lipid intensities both in gray andwhitemat-
ter and the differences in lipid intensities between control subjects and
AD patients in different stages of the disease. These images have been
obtained by using IMS in both negative (Fig. 4) and positive (Fig. 7)
ion detection modes.
In respect of the results obtained in positive ion mode, the levels of
only a few lipid specieswere signiﬁcantly changed inADpatients.More-
over, these lipid species do not follow a clear pattern of speciﬁc types of
molecules (as was the case of the decrease in ST species in negative
mode). The intensity of the signal of two lipid species was modiﬁed in
cortical gray matter: phosphatidic acid (PA) (36:2) + K+ (Control
50.9 ± 1.3% vs AD I–II 33.4 ± 3.6%, p b 0.05) and PA (38:2) + K+ (Con-
trol 8.3±0.5 vsAD I–II 2.2±0.3, p b 0.05). Their lowest intensitieswere
detected in the earliest stages of AD (Fig. 5, Table 4).
On the contrary, in cortical white matter we observed three lipid
species with low intensities in AD patients using positive ion detection
mode: PC (32:0) (Control 13.1 ± 4.2 vs AD V–VI 3.9 ± 0.5%, p b 0.05),
sphingomyelin (SM) (d18:1/18:0) (Control 7.4 ± 1.3% vs AD III–IV 2.3
± 0.8%, p b 0.05) and glucosylceramide (GlcCer) (d32:1)+K+ (Control
18.1 ± 1.1% vs AD III-IV 10.7 ± 1.3%, p b 0.05) (Fig. 6, Table 5).
4. Discussion
Lipid homeostasis is essential to good health and a deregulation of
lipid metabolism plays an important role in many human diseases, in-
cluding some neurological pathologies. In recent years, some experi-
mental evidence indicates that impairments in some metabolic lipid
pathways could be involved in the development of AD [3,52–54]. The
analysis of complex lipidmixtures through the development of soft ion-
ization techniques (MALDI and electrospray ionization, ESI), allow us to
study in greater detail these lipid pathways. The advancesmade inmass
spectrometry technologies during recent years have given rise to the in-
creasingly important ﬁeld of lipidomics, which provides us with new
opportunities to understand the metabolism and signaling by lipids in
different physiological conditions and diseases [55,56]. The present
study uses IMS, to determine the involvement of changes in the lipid
composition in the neurodegenerative processes, which occur in AD,
and could indicate that there is degradation of structural cell membrane
molecules. Therefore, we have tried to assess the differences in lipid
species in human brain samples from prefrontal cortex of AD patients
at different Braak's stages (I–II, III–IV, V–VI) by using the MALDI-IMS
assay. The study was performed both in positive and negative ionectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Table 5
Percentage of the relative intensity of representative lipids inwhite matter of postmortem human frontal cortex of controls and Alzheimer disease patients in positive ion detectionmode.
The maximal peak is the most intense peak of the spectrum, in this case 798.60 PC (34:1) + K+ which is set at 100%.
Assignment Cal m/z Exp m/z % intensity
Control AD I–II AD III–IV AD V–VI
(−) – 610.4447 8.2 ± 2.3 3.4 ± 0.7 3.2 ± 0.2a 3.1 ± 0.3
GlcCer (d32:1) + K+ 710.4968 710.4902 18.1 ± 1.1 10.7 ± 2.1 10.7 ± 1.3a 13.2 ± 1.1
SM (d18:1/18:0) 731.6067 731.6069 7.4 ± 1.3 4.1 ± 2.7 2.3 ± 0.8a 3.3 ± 0.4
PC (32:0) 734.5654 734.5688 13.1 ± 4.2 6.4 ± 1.3 6.4 ± 1.5 3.9 ± 0.2b
PA (36:2) + K+ 739.4691 739.4683 49.9 ± 1.8 43.7 ± 5.6 41.9 ± 6.2 39.4 ± 1.8
PA (38:2) + Na+ 751.5258 751.5248 4.9 ± 2.1 6.6 ± 0.8 4.9 ± 0.9 4.5 ± 0.6
SM (d18:1/18:0) + Na+ 753.5886 753.5889 15.8 ± 3.4 14.6 ± 2.9 16.2 ± 3.6 12.3 ± 1.9
PC (32:0) + Na+ 756.5519 756.5522 5.8 ± 0.5 7.3 ± 1.6 5.2 ± 1.6 6.5 ± 0.6
PC (34:1) 760.5856 760.5856 47.5 ± 11.2 56.6 ± 14.3 24.2 ± 2.9 35.5 ± 4.2
PA (38:2) + K+ 767.4988 767.5004 15.1 ± 1.4 14.0 ± 2.6 38.6 ± 5.6 10.5 ± 1.9
SM (d18:1/18:0) + K+ 769.5626 769.5629 30.1 ± 2.0 24.8 ± 2.3 11.5 ± 2.4 26.9 ± 1.2
PC (32:0) + K+ 772.5259 772.5271 17.8 ± 2.2 15.5 ± 1.3 25.3 ± 2.2 10.6 ± 1.4b
(−) – 776.5951 13.7 ± 4.1 12.5 ± 2.3 12.2 ± 1.3 10.5 ± 1.3
PC (34:1) + Na+ 782.5675 782.5691 43.9 ± 9.4 61.0 ± 8.8 9.0 ± 1.8 49.7 ± 7.0
PC (36:3) 784.5856 784.5743 6.7 ± 1.2 7.1 ± 1.1 61.0 ± 9.1 5.6 ± 0.5
PC (36:1) 788.6157 788.6195 18.0 ± 2.8 18.3 ± 4.8 6.6 ± 0.7 9.2 ± 0.5
(−) – 792.5689 13.9 ± 0.9 11.3 ± 2.6 111.9 ± 3.9 17.1 ± 2.6
PC (34:2) + K+ 796.5259 796.5248 4.7 ± 0.6 5.2 ± 0.1 9.7 ± 1.5 5.0 ± 0.7
PC (38:5) 808.5851 808.5844 8.4 ± 2.6 10.0 ± 1.7 4.8 ± 0.5 7.6 ± 1.3
PC (36:1) + Na+ 810.5988 810.6004 21.7 ± 3.9 20.7 ± 2.9 8.6 ± 2.4 14.1 ± 0.7
PC (36:2) + K+ 824.5571 824.5576 14.5 ± 1.2 15.9 ± 0.6 2 1.6 ± 3.7 15.4 ± 1.5
PC (36:1) + K+ 826.5728 826.5757 34.5 ± 0.9 35.7 ± 3.5 13.7 ± 2.8 25.1 ± 1.6
SM (42:2) + Na+ 835.6663 835.6684 19.5 ± 3.7 16.0 ± 2.7 30.5 ± 4.6 15.8 ± 1.5
SM (42:2) + K+ 851.6403 851.6411 30.9 ± 1.8 23.5 ± 2.6 14.3 ± 2.5 29.2 ± 3.4
Data aremean±SEM. The p valueswere calculated by theKruskal-Wallis non-parametric test followed byDunn's test. Control (n=5), AD I–II (n=5), AD III–IV (n=5), ADV–VI (n=5).
(−): unidentiﬁed lipid species; Cal: calculated, Exp: experimental.
a AD III–IV vs control.
b AD V–VI vs control.
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cies. Usually, thephospholipid species recorded in positive ion detection
mode include PA, PC and SM, and in negative mode the most common
lipids detected are PE, ST, PS and PI.
The main changes we have observed in the samples from AD pa-
tients were in ST species, a class of lipid molecules that are synthesized
predominantly by oligodendrocytes. These are multi-functional mole-
cules involved in the physiology of different tissues and systems includ-
ing the peripheral and central nervous systems [57–59]. In the CNS, the
ST are negative regulators for the differentiation and survival of the oli-
godendrocytes duringmyelination processes [60,61]. Studies in a ST de-
ﬁcient mouse model have shown the presence of structural
abnormalities and loss of axonal conduction [62]. Other studies demon-
strate the regulation of ST metabolism by apolipoprotein E (APOE) [47,
63], and the APOE ɛ4 allele is a risk factor for AD [6,64,65].
We report a signiﬁcant reduction of relative intensity in different ST
species in patients at different clinical stages of AD, in both cortical gray
and white matter in comparison with the maximum intensity peak PI
(38:4) and ST (24:1) respectively.
Nevertheless, as the observed ST relative intensity depletion was
similar in all stages of the disease, this implies that there is a ST deﬁcien-
cy from the onset of AD. An important conclusion, whichmay be drawn
from our study, is that ST depletion is a metabolic impairment possibly
related to synaptic dysfunction and neurodegeneration present in AD
from its earliest stages. The reduction of ST molecules in AD has previ-
ously been described by other research groups, and it has been demon-
strated that this ST depletion speciﬁcally affects AD patients and does
not appear in other neurodegenerative diseases, such as Parkinson's dis-
ease and Lewy body dementia [18,19,66]. Furthermore, ST has been
used in plasma samples to distinguish between elderly control and AD
patients [67]. In addition, a recent IMS study using experimentalmodels
exposed to cigarette smoke describes changes of ST species in the fron-
tal lobe [68], thereby, supporting the possible relationship between cig-
arette smoking and the risk of developing AD [69]. A recent study
reported no changes in the distribution of ST in temporal lobe brainPlease cite this article as: E. Gónzalez de San Román, et al., Imagingmass s
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1samples from three AD patients, but they do not discriminate between
the different stages of the disease [70].
Themetabolic mechanisms, which produce the reduction in speciﬁc
ST species observed in the frontal cortex of AD patients are still un-
known. It has been suggested that an accelerated degradation of ST
could lead to the production of ceramides (Cer). Some authors have re-
ported elevated levels of Cer in AD brains compared to non-affected
subjects [22,71,72]. We observed an increase in CPI and CPE, but not
in other Cer species previously reported. IMS allows anatomical detec-
tion without puriﬁcation artifacts, but the ion suppression generated
by MALDI-IMS could reduce the ability to detect molecular species of
low abundance [73]. Moreover, the matrix (MBT) has a molecular
weight (167.25) and can produce ionization products in a mass range
similar to some Cer, thereby masking their detection. It has been
shown that Cer species are able to stabilize the APP cleaving enzyme 1
(BACE1), promoting Aβ biogenesis [74,75]. On the other hand, a reduc-
tion of Cer levels leads to a reduced secretion of APP and Aβ in human
neuroblastoma cells [76]. Thus, it has been suggested that Cer and Aβ
could interact and induce neuronal death in AD [22]. In addition, in
the APPsw transgenic mice model of familial AD, there is also ST deple-
tion in cerebellum, but less than in cortex, supporting the idea that Aβ
could be associated with ST deﬁciency, since Aβ accumulation does
not occur to a signiﬁcant extent in cerebellum [47,77].
In KO mice for the lipoprotein receptor-related protein 1 (LPR1),
which is related to APOE in the transport and metabolism of plasma
lipids and Aβ clearance, deﬁcits in brain lipidmetabolism have been de-
scribed, characterized by decreased levels in cholesterol, ST and
galactosylceramide. These lipid alterations positively correlate with
synapse loss, neuroinﬂammation, memory loss and signs of neurode-
generation [78].
Due to themodiﬁcations observed in negative ion detectionmode in
AD patient's relative intensities, it is necessary to study ST during the
earliest or even from prodromal stages of the disease. Speciﬁc lipid de-
regulation could have primary effects on the other neurodegenerative
processes, including the formation of senile plaques and neuroﬁbrillarypectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
Fig. 7. The image shows the distribution of some representative lipid species thatwere foundmodiﬁed in gray orwhitematter areas of the frontal cortex fromhumanbrain tissue (controls
and AD patients at three different stages of the disease). The spectra were recorded with 150 μm spacing. Ten shots were accumulated at each point with the spectrometer working in
positive ion mode. Laser power was set at 15–20 μJ. Bar : 3 mm.
9E. Gónzalez de San Román et al. / Biochimica et Biophysica Acta xxx (2017) xxx–xxxtangles. In addition, the levels of speciﬁc ST species could be considered
as biomarkers for AD.
We also found other changes, such as the decrease of two PA species
in gray matter in positive ion detection mode when normalized to PC
(34:1) intensity (the most abundant species), which is in agreement
with previous studies that reported a decrease of PA in temporal gyrus
of AD patients [17]. Another study demonstrated that anionic phospho-
lipids, predominantly PA, diphosphatidyl glycerol (DPG), PS, and PI, in-
teract with Aβ peptide, in particular with Aβ (1–43) and Aβ (1–42),
increasing the ﬁbrillization of Aβ [79,80]. Interestingly, in our study,
we found two PA species decreased in frontal cortex of AD patients,Please cite this article as: E. Gónzalez de San Román, et al., Imagingmass sp
Alzheimer's disease, Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1but not the DPG, PS or PI lipid species. Accordingly, in early stages of
AD, cerebral PE, PI and PS were unchanged in both white and graymat-
ter [18]. Other authors have reported a decrease in PI in temporal and
occipital cortex, and in cerebellum [17,81,82]. All these studies used tra-
ditional analytical techniques for phospholipid proﬁling, which require
large brain samples and use tissue homogenates and extracts that
could lead to cross contamination between different brain regions of
gray and white matter. However, we minimized the sample size and
the possible contamination between different brain regions, as
MALDI-IMSwas performedwith tissue sections and gave anatomical lo-
calization of the lipids all over the tissue slice.ectrometry (IMS) of cortical lipids from preclinical to severe stages of
016/j.bbamem.2017.05.009
10 E. Gónzalez de San Román et al. / Biochimica et Biophysica Acta xxx (2017) xxx–xxxFinally, in this study we observed a decrease in GlcCer, SM and PC,
when normalized to PC (34:1) (the most abundant species), in white
matter. Recent studies revealed contradictory results about SM levels
in AD depending on the brain areas analyzed and on the analytical tech-
nique used. Some authors have described unchanged SM levels in CSF,
and extracts from cerebellum, middle frontal gyrus white matter of
frontal cortex [18,22], whilst others have described an increase in CSF,
middle frontal gyrus gray matter and cerebellum [17,64,82], or a de-
crease in SM levels in middle frontal gyrus [20]. We found that there
is a decrease in one speciﬁc SM species with the progression of the dis-
ease, SM (d18:1/18:0). The oxidative stress induced by Aβ could lead to
an increase in Cer levels, as described above.Many studies have claimed
a decrease in PC in plasma, brain homogenates and brain tissue sections
from AD patients [28,83,84], especially in PC containing
docosahexaenoic acid (DHA). We have detected two different DHA-PC
(38:6) and (40:6), but both of them without signiﬁcant changes be-
tween controls and patients. However, we have observed a decrease
of PC (32:0) relative intensity, a PC with two palmitic acids in its struc-
ture, in whitematter of the frontal cortex. A recent study has stated that
palmitoylation of APP regulates amyloidogenic processing [85]. The
lower intensities of PC (32:0) could be an indication of the release of
palmitic acids and the subsequent palmitoylation of APP during the pro-
gression of the disease.
In summary, the present study shows the anatomical localization of
some lipids species that are modiﬁed during the progression of the AD
in frontal cortex when expressed as relative intensity of the most abun-
dant species. The identiﬁed ST species could be involved in the patho-
genesis of the disease and be used as markers for AD.
A similar study of other brain areas affected by AD such as hippo-
campus, nucleus basalis ofMeynert and amygdalawould lead to a better
understanding of lipid adaptations during the progression of the
disease.
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